Survival Improved With Lobectomy, Segmentectomy in Early NSCLC
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 28, 2025 -- For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are associated with improved long-term survival compared with wedge resection, according to a study presented at the annual meeting of The Society of Thoracic Surgeons, held from Jan. 24 to 26 in Los Angeles.
Christopher Seder, M.D., from the Rush University Medical Center in Chicago, and colleagues analyzed data from 32,340 patients undergoing lung resection surgery for stage IA NSCLC from 346 U.S. institutions: 61.2, 13.2, and 25.6 percent underwent lobectomy, segmentectomy, and wedge resection, respectively.
The researchers found that lobectomy was associated with improved survival compared with sublobar resection (hazard ratio for overall survival [OS] and lung-cancer specific survival [LCSS], 0.87 and 0.91, respectively), specifically compared with wedge resection (hazard ratios, 0.84 and 0.88 for OS and LCSS, respectively), but not segmentectomy. Compared with wedge resection, segmentectomy was associated with improved survival (hazard ratios, 0.88 and 0.91 for OS and LCSS, respectively). In a sensitivity analysis excluding pathologic-upstaged cases, similar improved survival was seen for lobectomy versus sublobar and wedge resection; lobectomy survival was improved versus segmentectomy (hazard ratios, 0.88 and 0.89 for OS and LCSS, respectively), and survival was similar for segmentectomy and wedge resection.
"This research is a significant step forward in understanding the long-term implications of surgical choices for lung cancer patients," Seder said in a statement. "Using real-world data to complement randomized controlled trial findings offers surgeons additional context for tailoring treatment strategies."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
Presurgical Ablative Radiotherapy + Chemo Improves Pathologic Outcomes in Pancreatic Cancer
FRIDAY, July 11, 2025 -- Adding stereotactic ablative radiotherapy (SAbR) to neoadjuvant chemotherapy improves pathologic outcomes for patients diagnosed with pancreatic cancer...
A-Fib Catheter Ablation Cuts Risk for Ischemic Stroke After 30 Days, Mortality, Heart Failure Hospitalization
MONDAY, July 7, 2025 -- For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, mortality, and heart failure...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.